Melanoma Molecular Maps Projects



Title: List of c-MET inhibitors
Legend: The hepatocyte growth factor (HGF) / c-MET receptor tyrosine kinase pathway stimulates cell scattering, invasion, angiogenesis and protection from apoptosis, thus acting as a poweful oncogenic pathway. Many tumors, including melanoma [5], show c-MET pathway overactivation. This has led to the development of different anti-MET therapeutics such as Anisamycin, Anti-HGF antibodies (e.g. AMG102, L2G7), Anti-MET antibodies (e.g. DN30, OA-5D5), ARQ197, c-MET siRNA, Decoy c-MET, JNJ38877605, K252, MK2461, MP470, NK2, NK4, PF2341066, PHA665752, RPI 1, Sema domain, SGX523, SU11274, SU5416, Uncleavable HGF, XL880). REFERENCES: [1] Comoglio PM et al, Nat Rev Drug Discov 2008, 7:504-16. [2] Migliore C et al, Eur J Cancer 2008, 44:641-51. [3] Sattler M et al, Curr Oncol Rep 2007, 9:102-8. [4] Peruzzi B et al, Clin Cancer Res 2006, 12:3657-60. [5] Puri N et al, Clin Cancer Res 2007, 13:2246-53
Author: The MMMP Team (update: June 2008)

Search the site

Risk Assessment Tools

TNM Staging System | Total Dermoscopy Score | Thin Melanoma Prognosis |

Melanoma News

NCBI's Disclaimer and Copyright notice